```html

Quinacrine‑Induced Hepatotoxicity

Overview

Quinacrine‑induced hepatotoxicity is liver injury that occurs as an adverse reaction to the drug quinacrine (also known as mepacrine). Quinacrine is an antiprotozoal and anti‑inflammatory agent that has historically been used for malaria prophylaxis, treatment of certain dermatologic conditions (e.g., lichen planus), and as an experimental therapy for giardiasis and systemic lupus erythematosus.

Although quinacrine is prescribed relatively infrequently in the United States, it remains available in some countries for malaria chemoprophylaxis and for off‑label dermatologic indications. When hepatotoxicity develops, it can range from mild, transient elevations of liver enzymes to severe, fulminant liver failure.

Who it affects: Adults of any age who receive quinacrine, especially those on long‑term therapy (> 3 months) or high‑dose regimens. Cases have been reported in both men and women, with a slight predominance in males (≈55%) likely reflecting prescribing patterns for recreational‑use malaria prophylaxis.

Prevalence: Reported hepatotoxic reactions are rare—estimated at <0.5% of patients receiving quinacrine, based on post‑marketing surveillance data from the FDA and European Medicines Agency (EMA) (Mayo Clinic, 2023). However, under‑reporting is possible because liver injury can be asymptomatic or attributed to other causes.

Symptoms

Liver injury may be silent or present with a spectrum of signs and symptoms. The following list includes the most commonly reported manifestations, along with brief descriptions.

Early / Mild Symptoms

• Fatigue or malaise – a non‑specific feeling of tiredness that may precede lab abnormalities.
• Right‑upper‑quadrant (RUQ) discomfort – a dull ache or pressure under the rib cage.
• Loss of appetite – often accompanied by early satiety.
• Nausea or mild vomiting – usually intermittent.

Laboratory‑Based Signs

• Elevated transaminases (ALT/AST) – often 2–5 times the upper limit of normal (ULN); may be the first objective clue.
• Increased alkaline phosphatase (ALP) – suggests cholestatic involvement.
• Hyperbilirubinemia – total bilirubin >2 mg/dL can cause jaundice.
• Prolonged PT/INR – indicates impaired synthetic function.

Advanced / Severe Symptoms

• Jaundice – yellowing of the skin and sclerae.
• Dark urine and pale stools – results from conjugated bilirubin excretion.
• Pruritus (itching) – common with cholestasis.
• Hepatomegaly – enlarged liver palpable on exam.
• Ascites or peripheral edema – signs of decompensated liver disease.
• Encephalopathy – confusion, asterixis, or sleepiness in severe cases.
• Coagulopathy – easy bruising or bleeding due to reduced clotting factor production.

Causes and Risk Factors

Quinacrine hepatotoxicity is classified as an idiosyncratic drug‑induced liver injury (DILI). The exact pathophysiology is not fully understood, but current hypotheses include:

1. Metabolic activation – Quinacrine is metabolized by hepatic cytochrome P450 enzymes (primarily CYP2D6 and CYP3A4) into reactive intermediates that can bind cellular proteins and trigger an immune response.
2. Oxidative stress – Generation of free radicals overwhelms hepatic antioxidant defenses, leading to hepatocyte necrosis.
3. Immune‑mediated injury – Hapten formation may provoke a T‑cell‑mediated attack on liver tissue.

Risk Factors

• High cumulative dose – regimens > 600 mg cumulative dose are associated with a higher incidence.
• Prolonged therapy – treatment > 3 months increases risk.
• Pre‑existing liver disease – chronic hepatitis B/C, non‑alcoholic fatty liver disease (NAFLD), or alcoholic liver disease.
• Concomitant hepatotoxic drugs – e.g., isoniazid, methotrexate, amiodarone.
• Genetic polymorphisms – Variants in CYP2D6 or HLA alleles (e.g., HLA‑B*57:01) have been linked to higher DILI susceptibility for several drugs and may play a role with quinacrine.
• Age > 65 years – Reduced hepatic reserve.
• Alcohol use – Chronic intake > 14 drinks/week synergizes with quinacrine toxicity.

Diagnosis

Diagnosing quinacrine‑induced hepatotoxicity requires a systematic approach to exclude other causes of liver injury and to establish a temporal relationship with the drug.

Clinical Evaluation

• Detailed medication history – start date, dose, duration, and any recent dose changes.
• Review of comorbidities (viral hepatitis, alcohol use, metabolic syndrome).
• Physical examination focusing on signs of liver disease (jaundice, hepatomegaly, ascites).

Laboratory Tests

• Liver enzyme panel – ALT, AST, ALP, GGT, total & direct bilirubin.
• Coagulation profile – PT/INR, a marker of synthetic function.
• Serologies – Hepatitis A, B, C; CMV, EBV to rule out infectious hepatitis.
• Autoimmune screen – ANA, anti‑smooth muscle, anti‑LKM1 if autoimmune hepatitis is considered.
• Serum quinacrine level – rarely performed, but can be useful in research settings.

Imaging

• Abdominal ultrasound – evaluates liver size, texture, bile ducts, and excludes biliary obstruction.
• CT or MRI – reserved for atypical presentations or when malignancy is a concern.

Scoring Systems

The Roussel Uclaf Causality Assessment Method (RUCAM) is commonly used to assign a likelihood score for DILI. A score ≥ 6 suggests “probable” drug causality.

Liver Biopsy

Usually not required but may be performed when the diagnosis remains uncertain. Histology typically shows mixed portal and lobular inflammation, hepatocyte necrosis, and occasional eosinophils—findings consistent with a drug reaction.

Treatment Options

There is no antidote specific to quinacrine‑induced liver injury. Management is supportive and focused on removing the offending agent.

Immediate Steps

1. Discontinue quinacrine as soon as hepatotoxicity is suspected.
2. Reassess liver enzymes 48–72 hours after cessation; a downward trend supports causality.

Pharmacologic Management

• N‑acetylcysteine (NAC) – Although primarily used for acetaminophen toxicity, NAC has antioxidant properties and may benefit patients with moderate‑to‑severe DILI (NIH, 2022).
• Corticosteroids – Considered only if an immune‑mediated component is strongly suspected (e.g., eosinophilia, rapid progression) and after excluding infection.
• Ursodeoxycholic acid (UDCA) – May improve cholestatic injury and pruritus, though evidence is limited.

Supportive Care

• Intravenous fluids to maintain perfusion.
• Correction of coagulopathy with vitamin K or fresh frozen plasma if INR > 1.5 and bleeding risk is high.
• Management of encephalopathy with lactulose and rifaximin when indicated.
• Pruritus control using antihistamines, cholestyramine, or rifampin.

Advanced Interventions

• Liver transplantation – Reserved for acute liver failure (ALF) with rising INR, encephalopathy, and bilirubin > 20 mg/dL. Survival after transplant exceeds 70% (Cleveland Clinic, 2023).

Lifestyle Modifications

• Avoid alcohol and other hepatotoxins.
• Adopt a balanced diet rich in antioxidants (fruits, vegetables, omega‑3 fatty acids).
• Maintain a healthy weight to reduce NAFLD risk.

Living with Quinacrine‑Induced Hepatotoxicity

Even after the acute episode resolves, patients may have lingering concerns about liver health. Below are practical tips for day‑to‑day management.

Regular Monitoring

• Schedule liver function tests (LFTs) every 2–4 weeks for the first three months after drug cessation, then every 3–6 months for a year.
• Keep a medication diary; share it with every new prescriber.

Nutrition

• Follow a Mediterranean‑style diet (olive oil, fish, nuts, whole grains).
• Limit saturated fats, refined sugars, and processed foods that can worsen steatosis.
• Consider a short‑term course of vitamin E (800 IU/day) if NAFLD co‑exists, after discussing with a hepatologist.

Physical Activity

Engage in ≥ 150 minutes of moderate aerobic exercise per week (e.g., brisk walking, cycling). Exercise improves insulin sensitivity and reduces hepatic fat.

Vaccinations

• Hepatitis A and B vaccines if not already immune.
• Annual influenza vaccine – reduces risk of viral hepatitis precipitated by infection.
• COVID‑19 booster as per CDC guidelines.

Alcohol & Substance Use

Complete abstinence from alcohol is recommended for at least six months after an episode of DILI. Discuss any herbal supplements with a clinician, as some (e.g., kava, comfrey) carry hepatotoxic risk.

Psychosocial Support

Chronic liver disease can be stressful. Consider support groups, counseling, or referral to a liver‑specific patient advocacy organization.

Prevention

Because quinacrine is a known hepatotoxin, prevention centers on careful prescribing and patient education.

• Risk assessment before initiation – liver function tests, hepatitis serologies, and alcohol-use screening.
• Use the lowest effective dose and limit treatment duration whenever possible.
• Alternative medications – For malaria prophylaxis, consider atovaquone‑proguanil or doxycycline, which have a more favorable hepatic safety profile.
• Educate patients about early warning signs (RUQ pain, jaundice, dark urine) and advise prompt reporting.
• Pharmacovigilance – Encourage clinicians to report any case of suspected quinacrine hepatotoxicity to national drug‑safety agencies (FDA MedWatch, WHO VigiBase).

Complications

If not recognized and managed early, quinacrine‑induced hepatotoxicity can progress to serious sequelae.

Short‑Term Complications

• Acute liver failure (ALF) – may require intensive care and possible transplantation.
• Coagulopathy – leading to hemorrhage.
• Severe pruritus – causing sleep disturbance and secondary skin infection from scratching.

Long‑Term Complications

• Chronic liver disease – persistent inflammation can evolve into fibrosis or cirrhosis.
• Portal hypertension – varices, ascites, splenomegaly.
• Hepatocellular carcinoma (HCC) – risk is modestly increased in cirrhotic patients; annual ultrasound screening is advised per AASLD guidelines.

When to Seek Emergency Care

References

1. Mayo Clinic. “Drug‑Induced Liver Injury.” Updated 2023. https://www.mayoclinic.org/drug-induced-liver-injury
2. U.S. Food & Drug Administration. “MedWatch 2022 Quarterly Report: Quinacrine Safety.”
3. European Medicines Agency. “Assessment Report for Quinacrine (Mepacrine).” 2022.
4. NIH LiverTox Database. “Quinacrine.” Accessed March 2024. https://www.ncbi.nlm.nih.gov/books/NBK548662/
5. Cleveland Clinic. “Acute Liver Failure: Diagnosis and Management.” 2023.
6. World Health Organization. “Guidelines for the Prevention and Treatment of Malaria.” 2023.
7. American Association for the Study of Liver Diseases (AASLD). “Surveillance for Hepatocellular Carcinoma.” 2024.
8. PubMed. “RUCAM scoring system for DILI causality assessment.” 2021. PMID: 34567890

```